All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pam Bondi’s office had the opportunity to hold Trump University accountable for its fraudulent practices, which scammed ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...